


# RESEARCH REPORT



## GENOMIC CANCER PANEL AND PROFILING MARKETS

BY CANCER, BY APPLICATION, BY TISSUE AND BY GENE TYPE WITH  
SCREENING POTENTIAL MARKET SIZE.  
WITH EXECUTIVE AND CONSULTANT GUIDES  
2023-2027



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

|       |                                                                             |    |
|-------|-----------------------------------------------------------------------------|----|
| 1     | Market Guides .....                                                         | 24 |
| 1.1   | Cancer Panel Market - Strategic Situation Analysis .....                    | 25 |
| 1.2   | Large Comprehensive Cancer Panel Market - Situation Analysis .....          | 27 |
| 1.3   | Guide for Executives, Marketing, Sales and Business Development Staff ..... | 29 |
| 1.4   | Guide for Management Consultants and Investment Advisors.....               | 31 |
| 2     | Introduction and Market Definition .....                                    | 32 |
| 2.1   | What are Cancer Gene Panels and Profiling? .....                            | 33 |
| 2.2   | The Sequencing Revolution .....                                             | 36 |
| 2.3   | Market Definition .....                                                     | 38 |
| 2.3.1 | Revenue Market Size .....                                                   | 38 |
| 2.4   | Methodology.....                                                            | 40 |
| 2.4.1 | Methodology.....                                                            | 40 |
| 2.4.2 | Sources .....                                                               | 40 |
| 2.4.3 | Authors .....                                                               | 40 |
| 2.5   | Perspective: Healthcare and the IVD Industry .....                          | 42 |
| 2.5.1 | Global Healthcare Spending .....                                            | 42 |
| 2.5.2 | Spending on Diagnostics .....                                               | 43 |
| 2.5.3 | Important Role of Insurance for Diagnostics .....                           | 45 |
| 3     | Market Overview.....                                                        | 46 |

|         |                                                        |    |
|---------|--------------------------------------------------------|----|
| 3.1     | Players in a Dynamic Market.....                       | 47 |
| 3.1.1   | Academic Research Lab .....                            | 49 |
| 3.1.2   | Diagnostic Test Developer.....                         | 49 |
| 3.1.3   | Instrumentation Supplier .....                         | 50 |
| 3.1.4   | Chemical/Reagent Supplier.....                         | 50 |
| 3.1.5   | Pathology Supplier .....                               | 50 |
| 3.1.6   | Independent Clinical Laboratory .....                  | 51 |
| 3.1.7   | Public National/regional Laboratory .....              | 51 |
| 3.1.8   | Hospital Laboratory .....                              | 52 |
| 3.1.9   | Physicians Office Lab (POLs) .....                     | 52 |
| 3.1.10  | Audit Body .....                                       | 53 |
| 3.1.11  | Certification Body.....                                | 53 |
| 3.2     | Oncogenomics .....                                     | 55 |
| 3.2.1   | Carcinogenesis.....                                    | 55 |
| 3.2.2   | Chromosomes, Genes and Epigenetics.....                | 57 |
| 3.2.2.1 | Chromosomes.....                                       | 57 |
| 3.2.2.2 | Genes .....                                            | 59 |
| 3.2.2.3 | Epigenetics.....                                       | 62 |
| 3.2.3   | Cancer Genes .....                                     | 63 |
| 3.2.4   | Germline vs Somatic .....                              | 65 |
| 3.2.5   | Gene Panels, Single Gene Assays and Multiplexing ..... | 66 |
| 3.2.6   | Genomic Profiling.....                                 | 67 |
| 3.2.7   | The Comprehensive Assay .....                          | 68 |
| 3.2.8   | Changing Clinical Role .....                           | 68 |

|         |                                                                |    |
|---------|----------------------------------------------------------------|----|
| 3.2.9   | The Cancer Screening Market Opportunity .....                  | 70 |
| 3.3     | Cancer Management vs. Diagnosis .....                          | 71 |
| 3.3.1   | The Role of Risk Assessment .....                              | 71 |
| 3.3.2   | Diagnosis .....                                                | 71 |
| 3.3.3   | Managing .....                                                 | 72 |
| 3.3.4   | Monitoring .....                                               | 72 |
| 3.4     | Phases of Adoption – Looking into The Future .....             | 73 |
| 3.5     | Structure of Industry Plays a Part .....                       | 74 |
| 3.5.1   | Hospital Testing Share .....                                   | 74 |
| 3.5.2   | Economies of Scale .....                                       | 74 |
| 3.5.2.1 | Hospital vs. Central Lab .....                                 | 75 |
| 3.5.3   | Physician Office Lab's .....                                   | 76 |
| 3.5.4   | Physician's and POCT .....                                     | 77 |
| 3.6     | Currently Available Large Comprehensive Assays .....           | 77 |
| 3.7     | Pricing Profiling vs. Whole Exome (or Genome) Sequencing ..... | 80 |
| 3.7.1   | Medicare Profile Pricing .....                                 | 80 |
| 3.7.2   | Whole Exome Sequencing .....                                   | 80 |
| 4       | Market Trends .....                                            | 82 |
| 4.1     | Factors Driving Growth .....                                   | 83 |
| 4.1.1   | Level of Care .....                                            | 83 |
| 4.1.2   | Companion Dx .....                                             | 84 |
| 4.1.3   | Immuno-oncology .....                                          | 84 |
| 4.1.4   | Liability .....                                                | 84 |
| 4.1.5   | The Aging Effect .....                                         | 84 |

|       |                                                                                |     |
|-------|--------------------------------------------------------------------------------|-----|
| 4.2   | Factors Limiting Growth .....                                                  | 87  |
| 4.2.1 | State of knowledge.....                                                        | 87  |
| 4.2.2 | Genetic Blizzard.....                                                          | 88  |
| 4.2.3 | Protocol Resistance.....                                                       | 88  |
| 4.2.4 | Regulation and coverage.....                                                   | 88  |
| 4.3   | Instrumentation and Automation .....                                           | 89  |
| 4.3.1 | Instruments Key to Market Share.....                                           | 89  |
| 4.3.2 | Bioinformatics Plays a Role .....                                              | 89  |
| 4.4   | Diagnostic Technology Development .....                                        | 90  |
| 4.4.1 | Next Generation Sequencing Fuels a Revolution.....                             | 91  |
| 4.4.2 | Single Cell Genomics Changes the Picture .....                                 | 92  |
| 4.4.3 | Pharmacogenomics Blurs Diagnosis and Treatment.....                            | 93  |
| 4.4.4 | CGES Testing, A Brave New World .....                                          | 93  |
| 4.4.5 | Biochips/Giant magneto resistance based assay.....                             | 94  |
| 5     | Cancer Panels & Profiles Recent Developments .....                             | 95  |
| 5.1   | Recent Developments – Importance and How to Use This Section .....             | 96  |
| 5.1.1 | Importance of These Developments .....                                         | 96  |
| 5.1.2 | How to Use This Section.....                                                   | 96  |
| 5.2   | Cota, Genomic Testing Coop Ink Oncology Partnership.....                       | 96  |
| 5.3   | Euformatics, ViennaLab, Oncompass Win Liquid Biopsy Development Contract ..... | 97  |
| 5.4   | Prenetics' Cancer Profiling Test Receives FDA Clearance .....                  | 98  |
| 5.5   | Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy..... | 99  |
| 5.6   | Thermo Fisher Introduces Homologous Score for Cancer Profiling .....           | 101 |
| 5.7   | Genomic Test IDs Cancer Cells Early.....                                       | 103 |

|      |                                                                                                       |     |
|------|-------------------------------------------------------------------------------------------------------|-----|
| 5.8  | Caris Life Sciences to Offer Molecular Profiling Services .....                                       | 106 |
| 5.9  | Geneseeq to Build Lab for Cancer Profiling in Brazil .....                                            | 107 |
| 5.10 | Genetron Health Adds New Assays to Pipeline .....                                                     | 108 |
| 5.11 | Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay .....                                     | 111 |
| 5.12 | Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test<br>112                    |     |
| 5.13 | Cancer Screening Launch Approaches, Guardant Health Plans New<br>Comprehensive Assay .....            | 113 |
| 5.14 | Thermo Fisher, Oncocyte Ink Deal for Cancer IVDs .....                                                | 115 |
| 5.15 | Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep<br>Major Role ..... | 117 |
| 5.16 | Labcorp, CCORN Partner for Precision Oncology .....                                                   | 124 |
| 5.17 | Dante Labs Acquires Cambridge Cancer Genomics .....                                                   | 125 |
| 5.18 | Celemics, Strand Partner on Integrated Platform for NGS Analysis .....                                | 126 |
| 5.19 | Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries .....                             | 126 |
| 5.20 | Burning Rock Revenues Rise .....                                                                      | 132 |
| 5.21 | Caris Life Sciences to Expand Liquid Biopsy Testing .....                                             | 134 |
| 5.22 | OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence.....                                  | 137 |
| 5.23 | Intermountain and Myriad Combine Test Offering .....                                                  | 141 |
| 5.24 | Illumina, Geneseeq to Offer Cancer Testing Kits in China .....                                        | 146 |
| 5.25 | Exact Sciences to Offer End-to-End Cancer Testing .....                                               | 147 |
| 5.26 | Guardant Health Turns to Tumor Tissue Sequencing .....                                                | 150 |
| 5.27 | Tempus Inks Oncology Testing Collaboration With Bayer.....                                            | 154 |
| 5.28 | Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform<br>155           |     |

|      |                                                                                             |     |
|------|---------------------------------------------------------------------------------------------|-----|
| 5.29 | Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test .....                | 156 |
| 5.30 | Metastatic Cancer Markers Identified in Clinical WGS Study.....                             | 157 |
| 5.31 | Stitch Bio Bets on CRISPR Tech .....                                                        | 160 |
| 5.32 | Bayer, LifeLabs Launch Free NTRK Genetic Testing Program .....                              | 164 |
| 5.33 | Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx<br>165        |     |
| 5.34 | Progress, Challenges in Liquid Biopsy Reimbursement.....                                    | 166 |
| 5.35 | Israeli Startup Curesponse Raises \$6M.....                                                 | 170 |
| 5.36 | Invitae, ArcherDX Merge to Advance Precision Oncology Offerings .....                       | 171 |
| 5.37 | MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution<br>172 |     |
| 5.38 | NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program.....                 | 172 |
| 5.39 | Germline Results Guides Precision Therapy in Advanced Cancer .....                          | 173 |
| 5.40 | FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics .....              | 178 |
| 5.41 | ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers<br>179       |     |
| 5.42 | Labs Reporting Cancer Risk Mutations from Tumor Testing .....                               | 180 |
| 5.43 | Users Begin Integrating Genomics Data for Clinical Decision Support.....                    | 188 |
| 5.44 | Fujitsu Improves Efficiency in Cancer Genomic Medicine .....                                | 193 |
| 6    | Profiles of Key Players.....                                                                | 196 |
| 6.1  | 10x Genomics, Inc.....                                                                      | 197 |
| 6.2  | Abbott Laboratories.....                                                                    | 199 |
| 6.3  | AccuraGen Inc. ....                                                                         | 201 |
| 6.4  | Adaptive Biotechnologies.....                                                               | 202 |
| 6.5  | Aethlon Medical .....                                                                       | 204 |

|      |                                           |     |
|------|-------------------------------------------|-----|
| 6.6  | Agilent/Dako .....                        | 205 |
| 6.7  | Anchor Dx.....                            | 208 |
| 6.8  | ANGLE plc.....                            | 210 |
| 6.9  | ARUP Laboratories.....                    | 211 |
| 6.10 | AVIVA Systems Biology.....                | 213 |
| 6.11 | Baylor Miraca Genetics Laboratories ..... | 214 |
| 6.12 | Beckman Coulter Diagnostics.....          | 215 |
| 6.13 | Becton, Dickinson and Company .....       | 216 |
| 6.14 | BGI Genomics Co. Ltd .....                | 218 |
| 6.15 | Bioarray Genetics.....                    | 220 |
| 6.16 | Biocartis.....                            | 221 |
| 6.17 | Biocept, Inc.....                         | 222 |
| 6.18 | Biodesix Inc. ....                        | 223 |
| 6.19 | BioFluidica.....                          | 224 |
| 6.20 | BioGenex .....                            | 225 |
| 6.21 | BioIVT .....                              | 227 |
| 6.22 | Biolidics Ltd.....                        | 228 |
| 6.23 | bioMérieux Diagnostics.....               | 229 |
| 6.24 | Bioneer Corporation .....                 | 232 |
| 6.25 | Bio-Rad Laboratories, Inc.....            | 234 |
| 6.26 | Bio-Reference Laboratories.....           | 236 |
| 6.27 | Bio-Techne .....                          | 237 |
| 6.28 | Bioview .....                             | 239 |
| 6.29 | Bolidics .....                            | 240 |

|      |                                    |     |
|------|------------------------------------|-----|
| 6.30 | Boreal Genomics.....               | 241 |
| 6.31 | Bristol-Myers Squibb.....          | 242 |
| 6.32 | Burning Rock.....                  | 244 |
| 6.33 | Cardiff Oncology .....             | 246 |
| 6.34 | Caris Molecular Diagnostics .....  | 247 |
| 6.35 | Castle Biosciences, Inc. ....      | 248 |
| 6.36 | Celemics .....                     | 249 |
| 6.37 | CellMax Life .....                 | 250 |
| 6.38 | Cepheid (Danaher) .....            | 251 |
| 6.39 | Charles River Laboratories.....    | 253 |
| 6.40 | Circulogene.....                   | 254 |
| 6.41 | Clinical Genomics .....            | 255 |
| 6.42 | Cytolumina Technologies Corp. .... | 256 |
| 6.43 | Datar Cancer Genetics Limited..... | 257 |
| 6.44 | Diagnologix LLC.....               | 258 |
| 6.45 | Diasorin S.p.A. ....               | 259 |
| 6.46 | Element Biosciences .....          | 262 |
| 6.47 | Enzo Biochem .....                 | 263 |
| 6.48 | Epic Sciences.....                 | 265 |
| 6.49 | Epigenomics AG.....                | 266 |
| 6.50 | Eurofins Scientific .....          | 267 |
| 6.51 | Exact Sciences .....               | 270 |
| 6.52 | Fabric Genomics .....              | 271 |
| 6.53 | Fluxion Biosciences.....           | 272 |

|      |                                 |     |
|------|---------------------------------|-----|
| 6.54 | Freenome.....                   | 273 |
| 6.55 | FUJIFILM Wako Diagnostics.....  | 274 |
| 6.56 | GeneFirst Ltd.....              | 275 |
| 6.57 | Genetron Holdings .....         | 276 |
| 6.58 | GenomOncology .....             | 277 |
| 6.59 | GILUPI Nanomedizin.....         | 278 |
| 6.60 | Guardant Health .....           | 279 |
| 6.61 | HansaBiomed .....               | 280 |
| 6.62 | HeiScreen.....                  | 281 |
| 6.63 | Helomics.....                   | 282 |
| 6.64 | HTG Molecular Diagnostics ..... | 284 |
| 6.65 | iCellate.....                   | 286 |
| 6.66 | ICON PLC .....                  | 287 |
| 6.67 | Illumina .....                  | 288 |
| 6.68 | Incell Dx.....                  | 289 |
| 6.69 | Inivata .....                   | 290 |
| 6.70 | Integrated Diagnostics .....    | 291 |
| 6.71 | Invitae Corporation.....        | 292 |
| 6.72 | Invivogen .....                 | 293 |
| 6.73 | Invivoscribe .....              | 294 |
| 6.74 | Janssen Diagnostics .....       | 295 |
| 6.75 | KEW.....                        | 296 |
| 6.76 | Lunglife AI Inc .....           | 297 |
| 6.77 | MDNA Life SCIENCES, Inc.....    | 298 |

|       |                                                  |     |
|-------|--------------------------------------------------|-----|
| 6.78  | MDx Health .....                                 | 299 |
| 6.79  | Menarini Silicon Biosystems.....                 | 300 |
| 6.80  | Mesa Laboratories, Inc. ....                     | 301 |
| 6.81  | Millipore Sigma .....                            | 303 |
| 6.82  | Miltenyi Biotec .....                            | 304 |
| 6.83  | miR Scientific.....                              | 305 |
| 6.84  | Myriad Genetics/Myriad RBM .....                 | 306 |
| 6.85  | NantHealth, Inc. ....                            | 308 |
| 6.86  | Natera .....                                     | 310 |
| 6.87  | NeoGenomics .....                                | 312 |
| 6.88  | NGeneBio.....                                    | 314 |
| 6.89  | Novogene Bioinformatics Technology Co., Ltd..... | 316 |
| 6.90  | Oncocyte.....                                    | 318 |
| 6.91  | OncoDNA .....                                    | 319 |
| 6.92  | Oxford Nanopore Technologies .....               | 320 |
| 6.93  | Panagene .....                                   | 321 |
| 6.94  | Perkin Elmer.....                                | 322 |
| 6.95  | Personal Genome Diagnostics.....                 | 324 |
| 6.96  | Personalis.....                                  | 325 |
| 6.97  | Precipio .....                                   | 326 |
| 6.98  | Precision Medicine Group .....                   | 327 |
| 6.99  | PrecisionMed .....                               | 328 |
| 6.100 | Prenetics.....                                   | 329 |
| 6.101 | Promega .....                                    | 330 |

|       |                                   |     |
|-------|-----------------------------------|-----|
| 6.102 | Qiagen .....                      | 332 |
| 6.103 | QuidelOrtho .....                 | 334 |
| 6.104 | Rarecells SAS.....                | 336 |
| 6.105 | RareCyte .....                    | 337 |
| 6.106 | Roche Molecular Diagnostics ..... | 338 |
| 6.107 | ScreenCell .....                  | 340 |
| 6.108 | Sense Biodetection .....          | 341 |
| 6.109 | Siemens Healthineers .....        | 343 |
| 6.110 | simfo GmbH.....                   | 345 |
| 6.111 | Singlera Genomics Inc.....        | 346 |
| 6.112 | Singular Genomics .....           | 347 |
| 6.113 | Singulomics .....                 | 349 |
| 6.114 | SkylineDx .....                   | 351 |
| 6.115 | Standard BioTools .....           | 352 |
| 6.116 | Stilla Technologies .....         | 354 |
| 6.117 | Sysmex Inostics.....              | 355 |
| 6.118 | Tempus Labs, Inc. ....            | 356 |
| 6.119 | Thermo Fisher Scientific Inc..... | 357 |
| 6.120 | Todos Medical .....               | 360 |
| 6.121 | Ultima Genomics.....              | 361 |
| 6.122 | Variantyx .....                   | 362 |
| 6.123 | Vela Diagnostics.....             | 363 |
| 6.124 | Veracyte .....                    | 364 |
| 6.125 | Volition .....                    | 365 |

|       |                                                                         |     |
|-------|-------------------------------------------------------------------------|-----|
| 6.126 | Vortex Biosciences .....                                                | 366 |
| 6.127 | Vyant Bio.....                                                          | 367 |
| 7     | The Global Market for Cancer Gene Panels and Profiles.....              | 368 |
| 7.1   | Global Market Overview by Country .....                                 | 369 |
| 7.1.1 | Table – Global Market by Country.....                                   | 369 |
| 7.1.2 | Chart - Global Market by Country.....                                   | 370 |
| 7.2   | Global Market by Cancer Type - Overview.....                            | 371 |
| 7.2.1 | Table – Global Market by Cancer Type .....                              | 371 |
| 7.2.2 | Chart – Global Market by Cancer Type – Base/Final Year Comparison ..... | 372 |
| 7.2.3 | Chart – Global Market by Cancer Type – Base Year .....                  | 373 |
| 7.2.4 | Chart – Global Market by Cancer Type – Final Year.....                  | 374 |
| 7.2.5 | Chart – Global Market by Cancer Type – Share by Year .....              | 375 |
| 7.2.6 | Chart – Global Market by Cancer Type – Segment Growth .....             | 376 |
| 7.3   | Global Market by Application - Overview.....                            | 377 |
| 7.3.1 | Table – Global Market by Application .....                              | 377 |
| 7.3.2 | Chart – Global Market by Application – Base/Final Year Comparison ..... | 378 |
| 7.3.3 | Chart – Global Market by Application – Base Year .....                  | 379 |
| 7.3.4 | Chart – Global Market by Application – Final Year.....                  | 380 |
| 7.3.5 | Chart – Global Market by Application – Share by Year.....               | 381 |
| 7.3.6 | Chart – Global Market by Application – Segment Growth .....             | 382 |
| 7.4   | Global Market by Tissue - Overview .....                                | 383 |
| 7.4.1 | Table – Global Market by Tissue .....                                   | 383 |
| 7.4.2 | Chart – Global Market by Tissue – Base/Final Year Comparison.....       | 384 |
| 7.4.3 | Chart – Global Market by Tissue – Base Year.....                        | 385 |

|       |                                                                             |     |
|-------|-----------------------------------------------------------------------------|-----|
| 7.4.4 | Chart – Global Market by Tissue – Final Year .....                          | 386 |
| 7.4.5 | Chart – Global Market by Tissue – Share by Year .....                       | 387 |
| 7.4.6 | Chart – Global Market by Tissue – Segment Growth.....                       | 388 |
| 7.5   | Global Market Germline & Somatic - Overview.....                            | 389 |
| 7.5.1 | Table – Global Market Germline & Somatic .....                              | 389 |
| 7.5.2 | Chart – Global Market Germline & Somatic – Base/Final Year Comparison ..... | 390 |
| 7.5.3 | Chart – Global Market Germline & Somatic – Base Year .....                  | 391 |
| 7.5.4 | Chart – Global Market Germline & Somatic – Final Year.....                  | 392 |
| 7.5.5 | Chart – Global Market Germline & Somatic – Share by Year.....               | 393 |
| 7.5.6 | Chart – Global Market Germline & Somatic – Segment Growth .....             | 394 |
| 8     | Global Cancer Gene Panels & Profiles Markets – By Type of Cancer.....       | 395 |
| 8.1   | Comprehensive Panels & Profiles .....                                       | 396 |
| 8.1.1 | Table Comprehensive Testing – by Country.....                               | 396 |
| 8.1.2 | Chart - Comprehensive Testing Growth.....                                   | 397 |
| 8.2   | Breast Cancer Gene Testing .....                                            | 398 |
| 8.2.1 | Table Breast Cancer Gene Testing – by Country .....                         | 398 |
| 8.2.2 | Chart - Breast Cancer Testing Growth.....                                   | 399 |
| 8.3   | Colorectal Cancer Gene Testing .....                                        | 400 |
| 8.3.1 | Table Colorectal Cancer Gene Testing – by Country.....                      | 400 |
| 8.3.2 | Chart - Colorectal Cancer Gene Testing Growth .....                         | 401 |
| 8.4   | Gynecological Cancer Gene Testing .....                                     | 402 |
| 8.4.1 | Table Gynecological Cancer Gene Testing – by Country .....                  | 402 |
| 8.4.2 | Chart - Gynecological Cancer Gene Testing Growth.....                       | 403 |
| 8.5   | Blood Cancer Gene Testing.....                                              | 404 |

|        |                                                                             |     |
|--------|-----------------------------------------------------------------------------|-----|
| 8.5.1  | Table Blood Cancer Gene Testing – by Country .....                          | 404 |
| 8.5.2  | Chart - Blood Cancer Gene Testing Growth .....                              | 405 |
| 8.6    | Prostate Cancer Gene Testing.....                                           | 406 |
| 8.6.1  | Table Prostate Cancer Gene Testing – by Country .....                       | 406 |
| 8.6.2  | Chart - Prostate Cancer Testing Growth .....                                | 407 |
| 8.7    | Lung Cancer Gene Testing .....                                              | 408 |
| 8.7.1  | Table Lung Cancer Gene Testing – by Country.....                            | 408 |
| 8.7.2  | Chart - Lung Cancer Gene Testing Growth .....                               | 409 |
| 8.8    | Other Cancer Gene Testing.....                                              | 410 |
| 8.8.1  | Table Other Cancer Gene Testing – by Country .....                          | 410 |
| 8.8.2  | Chart - Other Cancer Gene Testing Growth .....                              | 411 |
| 9      | Global Cancer Gene Panels & Profiles Markets – By Type of Application ..... | 412 |
| 9.1    | Clinical Testing.....                                                       | 413 |
| 9.1.1  | Table Clinical Testing – by Country .....                                   | 413 |
| 9.1.2  | Chart - Clinical Testing Growth.....                                        | 414 |
| 9.2    | Pharmaceutical Testing .....                                                | 415 |
| 9.2.1  | Table Pharmaceutical Testing – by Country .....                             | 415 |
| 9.2.2  | Chart - Pharmaceutical Testing Growth.....                                  | 416 |
| 9.3    | Research Testing .....                                                      | 417 |
| 9.3.1  | Table Research Testing – by Country.....                                    | 417 |
| 9.3.2  | Chart - Research Testing Growth .....                                       | 418 |
| 10     | Global Cancer Gene Panels & Profiles Markets – By Tissue Type.....          | 419 |
| 10.1   | Solid Tissue.....                                                           | 420 |
| 10.1.1 | Table Solid Tissue Testing – by Country .....                               | 420 |

|        |                                                                                                       |     |
|--------|-------------------------------------------------------------------------------------------------------|-----|
| 10.1.2 | Chart – Solid Tissue Testing Growth .....                                                             | 421 |
| 10.2   | Liquid Tissue Testing .....                                                                           | 422 |
| 10.2.1 | Table Liquid Tissue Testing – by Country .....                                                        | 422 |
| 10.2.2 | Chart - Liquid Tissue Testing Growth.....                                                             | 423 |
| 11     | Global Cancer Gene Testing Markets – Germline and Somatic .....                                       | 424 |
| 11.1   | Global Market Somatic.....                                                                            | 425 |
| 11.1.1 | Table Somatic – by Country .....                                                                      | 425 |
| 11.1.2 | Chart - Somatic Testing Growth .....                                                                  | 426 |
| 11.2   | Global Market Germline .....                                                                          | 427 |
| 11.2.1 | Table Germline – by Country.....                                                                      | 427 |
| 11.2.2 | Chart - Germline Testing Growth .....                                                                 | 428 |
| 12     | Potential Market Opportunity Sizes.....                                                               | 429 |
| 12.1   | Potential Cancer Screening by Country: Lung, Breast & Colorectal.....                                 | 430 |
| 12.2   | Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer.....                       | 432 |
| 12.3   | Potential Market Size - Cancer Diagnosis.....                                                         | 434 |
| 12.4   | Potential Market Size – Therapy Selection.....                                                        | 436 |
| 13     | Appendices.....                                                                                       | 438 |
| 13.1   | Quarterly Actuals and Forecast Volumes and Revenues for Foundation Medicine and Guardant Health ..... | 439 |
| 13.2   | United States Medicare System: Clinical Laboratory Fees Schedule .....                                | 444 |
| 13.3   | FDA Approved Human Genetic Tests.....                                                                 | 547 |
| 13.4   | Pharmacogenomic Biomarkers in Drug Labeling.....                                                      | 559 |
| 13.5   | FDA Approved Pharmacogenomics Tests .....                                                             | 583 |

## Table of Tables

|                                                                        |     |
|------------------------------------------------------------------------|-----|
| Table 1 Market Players by Type .....                                   | 49  |
| Table 2 The Base Pairs.....                                            | 60  |
| Table 3 Current Assays .....                                           | 77  |
| Table 4 Relevant Pricing Table .....                                   | 80  |
| Table 5 Five Factors Driving Growth.....                               | 83  |
| Table 6 Four Factors Limiting Growth .....                             | 87  |
| Table 7 Key Diagnostic Laboratory Technology Trends .....              | 90  |
| Table 8 Next Generation Sequencing Technologies – Speed and Cost ..... | 91  |
| Table 9 - Global Cancer Panel Market by Region.....                    | 369 |
| Table 10 Global Market by Cancer Type .....                            | 371 |
| Table 11 Global Market by Application.....                             | 377 |
| Table 12 Global Market by Tissue .....                                 | 383 |
| Table 13 Global Market Germline & Somatic .....                        | 389 |
| Table 14 Comprehensive Testing by Country.....                         | 396 |
| Table 15 Breast Cancer Gene Testing by Country.....                    | 398 |
| Table 16 Colorectal Cancer Gene Testing by Country.....                | 400 |
| Table 17 Gynecological Cancer Testing by Country .....                 | 402 |
| Table 18 Blood Cancer Gene Testing by Country .....                    | 404 |
| Table 19 Prostate Cancer Gene Testing by Country .....                 | 406 |
| Table 20 Lung Cancer Gene Testing by Country.....                      | 408 |

|                                                                         |     |
|-------------------------------------------------------------------------|-----|
| Table 21 Other Cancer Gene Testing by Country .....                     | 410 |
| Table 22 Clinical Testing by Country .....                              | 413 |
| Table 23 Pharmaceutical Testing by Country .....                        | 415 |
| Table 24 Research Testing by Country.....                               | 417 |
| Table 25 Solid Tissue Testing by Country.....                           | 420 |
| Table 26 Liquid Tissue Testing by Country .....                         | 422 |
| Table 27 Somatic by Country .....                                       | 425 |
| Table 28 Germline by Country.....                                       | 427 |
| Table 29 Potential Screening Market: Lung, Breast & Colorectal.....     | 430 |
| Table 30 Potential Screening Market: Prostate, Other & All .....        | 432 |
| Table 31 Potential Cancer Diagnosis Market Size .....                   | 434 |
| Table 32 Potential Cancer Management Market Size .....                  | 436 |
| Table 33 Foundation - Guardant 2016-17 Quarterly Revenue & Volume ..... | 439 |
| Table 34 Foundation - Guardant 2018 Quarterly Revenue & Volume .....    | 440 |
| Table 35 Foundation - Guardant 2019 Quarterly Revenue & Volume .....    | 441 |
| Table 36 Foundation - Guardant 2020 Quarterly Revenue & Volume .....    | 442 |
| Table 37 Foundation - Guardant 2021 Quarterly Revenue & Volume .....    | 443 |
| Table 38 Laboratory Fee Schedule .....                                  | 444 |
| Table 39 FDA Approved Human Genetic tests .....                         | 547 |
| Table 40 Pharmacogenomic Biomarkers .....                               | 559 |
| Table 41 FDA Approved Pharmacogenomic Tests.....                        | 583 |

## Table of Figures

|                                                                      |     |
|----------------------------------------------------------------------|-----|
| Figure 1 VistSeq Hereditary Cancer Panel.....                        | 35  |
| Figure 2 Global Healthcare Spending .....                            | 43  |
| Figure 3 The Lab Test Pie .....                                      | 44  |
| Figure 4 The Road to Diagnostics .....                               | 47  |
| Figure 5 The Genomic Progression of Cancer.....                      | 56  |
| Figure 6 DNA Strands and Chromosomes .....                           | 57  |
| Figure 7 Karyogram of Human Chromosomes.....                         | 58  |
| Figure 8 Size of Various Genomes .....                               | 61  |
| Figure 9 Germline vs Somatic Mutations.....                          | 65  |
| Figure 10 Comparing Genomic Diagnostic and Traditional Testing ..... | 69  |
| Figure 11 The Changing Age of The World's Population.....            | 85  |
| Figure 12 Health Care Consumption by Age .....                       | 86  |
| Figure 13 Cancer Incidence - Age at Diagnosis.....                   | 86  |
| Figure 14 Base Year Country Global Share .....                       | 370 |
| Figure 15 Global Market by Cancer - Base vs. Final Year .....        | 372 |
| Figure 16 Cancer Panel Market Base Year.....                         | 373 |
| Figure 17 Cancer Panel Market Final Year .....                       | 374 |
| Figure 18 Cancer Type Share by Year .....                            | 375 |
| Figure 19 Cancer Type Segment Growth .....                           | 376 |
| Figure 20 Global Market by Cancer - Base vs. Final Year .....        | 378 |
| Figure 21 Cancer Panel Market Base Year.....                         | 379 |

|                                                               |     |
|---------------------------------------------------------------|-----|
| Figure 22 Cancer Panel Market Final Year .....                | 380 |
| Figure 23 Application Share by Year.....                      | 381 |
| Figure 24 Application Segment Growth .....                    | 382 |
| Figure 25 Global Market by Cancer - Base vs. Final Year ..... | 384 |
| Figure 26 Cancer Panel Market Base Year.....                  | 385 |
| Figure 27 Cancer Panel Market Final Year .....                | 386 |
| Figure 28 Tissue Share by Year .....                          | 387 |
| Figure 29 Tissue Segment Growth.....                          | 388 |
| Figure 30 Germline & Somatic - Base vs. Final Year .....      | 390 |
| Figure 31 Germline & Somatic Market Base Year .....           | 391 |
| Figure 32 Germline & Somatic Market Final Year.....           | 392 |
| Figure 33 Germline & Somatic Share by Year .....              | 393 |
| Figure 34 Germline & Somatic Segment Growth .....             | 394 |
| Figure 35 Comprehensive Testing Growth.....                   | 397 |
| Figure 36 Breast Cancer Testing Growth.....                   | 399 |
| Figure 37 Colorectal Cancer Gene Testing Growth .....         | 401 |
| Figure 38 Gynecological Cancer Testing Growth .....           | 403 |
| Figure 39 Blood Cancer Gene Testing Growth .....              | 405 |
| Figure 40 Prostate Cancer Gene Testing Growth .....           | 407 |
| Figure 41 Lung Cancer Gene Testing Growth.....                | 409 |
| Figure 42 Other Cancer Gene Testing Growth .....              | 411 |
| Figure 43 Clinical Testing Growth .....                       | 414 |
| Figure 44 Pharmaceutical Testing Growth.....                  | 416 |
| Figure 45 Research Testing Growth .....                       | 418 |

Figure 46 Solid Tissue Testing Growth..... 421

Figure 47 Liquid Tissue Testing Growth..... 423

Figure 48 Somatic Testing Growth ..... 426

Figure 49 Germline Testing Growth ..... 428